China Biologic Products (CBPO) Reports Q1 EPS of $0.94

China Biologic Products (NASDAQ: CBPO) reported Q1 EPS of $0.94, versus $0.87 reported last year. Revenue for the quarter came in at $85.6 million, versus $70.4 million reported last year.

Financial Outlook

For the full year of 2016, the Company reiterates its full year forecast of total sales growth of 21% to 23% in RMB terms and non-GAAP adjusted net income growth of 24% to 26% in RMB terms over 2015 financial results. This guidance does not factor in any potential foreign currency translation impact. Having previously adopted an exchange rate of approximately RMB6.21 = $1.00 based on weighted average quarterly exchange rates in 2015 in translating 2015 financial results, the Company expects that the total sales and non-GAAP adjusted net income in USD terms in 2016 will be adversely affected by the foreign currency translation impact.

For earnings history and earnings-related data on China Biologic Products (CBPO) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Lument Finance Trust (LFT) Misses Q2 EPS by 17c
• Birchtech Corp. (BCHT) Misses Q2 EPS by 7c